| Identification | Back Directory | [Name]
BAY-41-8543 | [CAS]
256498-66-5 | [Synonyms]
BAY-41-8543
BAY-41-8543 Exclusive
BAY 41-8543
(BAY 418543)
2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-5-morpholin-4-ylpyrimidine-4,6-diamine
2-[1-[(2-Fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-morpholinyl)-4,6-pyrimidinediamine
4,6-Pyrimidinediamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-morpholinyl)-
BAY 418543,vascular,systemic,antiplatelet,vasodilator,soluble,pulmonary,orally,nitric,beds,cardiovascular,BAY 41 8543,Guanylate Cyclase,Inhibitor,sGC,BAY 41-8543,oxide,inhibit | [Molecular Formula]
C21H21FN8O | [MDL Number]
MFCD18382081 | [MOL File]
256498-66-5.mol | [Molecular Weight]
420.44 |
| Chemical Properties | Back Directory | [Boiling point ]
599.7±50.0 °C(Predicted) | [density ]
1.55±0.1 g/cm3(Predicted) | [solubility ]
DMF: 3 mg/ml; DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml | [form ]
A crystalline solid | [pka]
5.18±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
BAY 41-8543, is a Guanylyl cyclase (sGC) stimulator, increasing the activity of recombinant sGC dose-dependently, from 0.1 nM to 100 μM, up to 92-fold. BAY 41-8543 reduces pulmonary vascular resistance and protects right ventricular (RV)function. It also inhibits collagen-induced platelet aggregation, and promotes lipid uptake into brown adipose tissue and increases energy expenditure in mice. It has also shown Antihypertensive activity. | [Definition]
ChEBI: BAY-41-8543 is a pyrazolopyridine. | [in vivo]
BAY 41-8543 (10-100 μg/kg; IV) produces small decreases in pulmonary arterial pressure, larger dose-dependent decreases in systemic arterial pressure, and increases in cardiac output[1].
BAY 41-8543 (0.003, 0.01, 0.03, 0.1, and 0.3?mg/kg; iv) produces a dose-dependent and long-lasting decrease in blood pressure in anaesthetized rats. The blood pressure lowering effect of BAY 41-8543 lasts longer than the observation period of 30?min. BAY 41-8543 (0.1, 0.3 and 1.0?mg?kg; oral) has maximal blood pressure lowering effects. The blood pressure lowering effects of the highest doses of BAY41-8543 lasts longer than the observation period of 120?min[2].
BAY 41-8543 (3?mg/kg; p.o.; twice daily; for 5 weeks) completely prevents the development of the increase in systolic blood pressure in 18-week-old renin transgenic rats (TGR(mRen2)27) on L-NAME treatment. BAY 41-8543 dramatically increases survival[2].
| Animal Model: | Adult male Sprague-Dawley rats weighing 325-450 g[1] | | Dosage: | 10, 30, and 100 μg/kg | | Administration: | IV | | Result: | Produced small decreases in pulmonary arterial pressure, larger dose-dependent decreases in systemic arterial pressure, and increases in cardiac output.
|
| [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|